National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials
News Jul 27, 2007
National Stem Cell Holding, Inc. together with Michael Cohen and Jacob Cohen announced the filing of a provisional patent application for a newly discovered group of cellular derived biomaterials that appear to promote tissue repair in a variety of wound care applications.
These new biomaterials are derived from the company's proprietary stem cell and progenitor cell lines. Preclinical studies with these newly discovered biomaterials appear to enhance the rate of tissue repair and healing and of the strength of healed wounds.
The Company believes that further research and development will clarify indications thus far that these biomaterials may be useful for a wide variety of acute and chronic wounds including but not limited to, burns, surgery related, and diabetes related.
Government Accounting Office (GAO) statistics show a tremendous need for wound care treatment. Each year, according to the GAO, approximately five million Americans suffer from chronic wounds caused by diabetes, circulatory problems and many other conditions.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.